Thomas H. Glocer - Jun 30, 2021 Form 4 Insider Report for Merck & Co., Inc. (MRK)

Role
Director
Signature
/s/ Kelly E. W. Grez as Attorney-in-Fact for Thomas H. Glocer
Stock symbol
MRK
Transactions as of
Jun 30, 2021
Transactions value $
$8,750
Form type
4
Date filed
7/2/2021, 09:38 AM
Previous filing
Jun 3, 2021
Next filing
Oct 1, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MRK Common Stock 5.1K Jun 30, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRK Phantom Stock Award $8.75K +113 +0.14% $77.77 78.4K Jun 30, 2021 Common Stock 113 Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1-for-1
F2 Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.
F3 Holdings include shares acquired in dividend reinvestment transactions.
F4 Holdings reflect the adjustment that occurred as of June 2, 2021 in connection with the Organon spin-off as described in the registration statement on Form 10 filed with the SEC for Organon & Co. (the "Form 10"). As reported in the Form 10, each Merck phantom share outstanding under the Merck Deferred Compensation Plan as of immediately prior to the distribution date was converted on the distribution date into an adjusted Merck phantom share with the number of units represented by such award adjusted to preserve the aggregate value of the original Merck phantom shares as measured before and immediately after the distribution.